<!DOCTYPE html>
<html lang="en" dir="ltr">

<head>
  <title>IgAN Patient Case - About Carlos's Experience</title>
  <meta name="description" content="Discover Carlos’s experience with IgAN. Follow his case to see how this chronic kidney condition can lead to end-stage kidney disease">
  {{> ../templates/header }}
  <link href="../styles.bundle.css" rel="stylesheet" type="text/css">
</head>

<body>
  <!-- Google Tag Manager (noscript) -->
  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-WZLFQZR3" height="0" width="0"
      style="display:none;visibility:hidden"></iframe></noscript>
  <!-- End Google Tag Manager (noscript) -->
  <main class="wrapper" data-page-id="pat-profile-carlos" data-path-level="2">

    {{> ../templates/nav }}
    {{> ../templates/interstitial }}

    <div class="progress-dots-container"></div>

    {{> ../templates/mestc-score-modal }}

    <img id="scroll-arrow" class="update-path" src="./assets/images/scroll-arrow.svg" alt="Scroll arrow down" />

    <div id="mobile-bio-tray" class="mobile-bio-tray">
      <div id="tray-close">
        <p>Baseline Assessment at Biopsy</p>
        <img src="./assets/images/back-arrow.svg" class="update-path arrow" alt="Back arrow"/>
      </div>

      <p class="name">Carlos, 40</p>

      {{> ../templates/carlos-bio }}

      <div class="extra-section">
        <p class="extra-footnote">*Image used with permission from the Renal Fellow Network, from: Gallan A. Kidney Biopsy of the Month.
          Published July 29, 2019. Available at <a class="format-url link-color" target="_blank"
            href="https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/">https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/</a>.
        </p>
    
        <p class="extra-footnote">ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; CKD, chronic kidney disease; eGFR,
          estimated glomerular filtration rate; IgA, immunoglobulin A; MEST-C, mesangial hypercellularity (M), endocapillary
          hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent
          (C); PAS, periodic acid-Schiff.</p>
      </div>
    </div>

    <div id="carlos-bio-tray-2" class="mobile-bio-tray">
      <div id="tray-close">
        <p>Assessment after 2 years</p>
        <img src="./assets/images/back-arrow.svg" class="update-path arrow" alt="Back arrow"/>
      </div>

      <p class="name">Carlos, 42</p>

      {{> ../templates/carlos-bio-42 }}

      <div class="extra-section">
        <p class="extra-footnote">*Image used with permission from the Renal Fellow Network, from: Gallan A. Kidney Biopsy of the Month.
          Published July 29, 2019. Available at <a class="format-url link-color" target="_blank"
            href="https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/">https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/</a>.
        </p>
    
        <p class="extra-footnote">ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; CKD, chronic kidney disease; eGFR,
          estimated glomerular filtration rate; IgA, immunoglobulin A; MEST-C, mesangial hypercellularity (M), endocapillary
          hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent
          (C); PAS, periodic acid-Schiff.</p>
      </div>
    </div>

    <!-- //////////////////// SECTION 1 ///////////////////// -->

    <section class="" data-section-id="1" data-section-name="Carlos Patient Information" data-dot-label="走近卡洛斯">
      <div class="two-column">

        <div id="left-bio">
          <img src="./assets/images/profiles/carlos-profile.png" class="update-path bio-pic"
            alt="" />
          
            {{> ../templates/carlos-bio }}
        </div>

        <div class="right-side">
          <img src="./assets/images/profiles/carlos-profile.png" class="update-path bio-pic conditional-render" alt=""/>
          <p class="name conditional-render">Carlos, 40</p>

          <h1 class="sect-1-header">卡洛斯是一位40岁的西班牙裔男性，IT专业人士，经营着自己的公司。</h1>

          <p class="bold">在过去的3个月里，卡洛斯开始感到疲劳、体重增加，并且脚踝出现肿胀，<br class="desktop-only">他注意到这点是因为他的鞋子比平时更紧了。</p>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>在体检中被发现高血压和2级水肿。</span></li>
          </ul>

          <div class="divider"></div>

          <h4 class="purple">卡洛斯到肾病科医生处就诊</h4>

          <div class="flex">
            <div class="workup">
              <img class="icon update-path" src="./assets/images/gauge-icon.svg" alt="" />
              <p>肾功能下降，<br class="desktop-only">提示CKD 3a期</p>
            </div>
            <div class="workup">
              <img class="icon update-path" src="./assets/images/vial-icon.svg" alt="" />
              <p>显微镜下血尿，<br class="desktop-only" />
                蛋白尿 <span class="nowrap">6 g/d</span></p>
            </div>
          </div>
          <div class="flex">
            <div class="workup">
              <img class="icon update-path" src="./assets/images/kidneys-icon.svg" alt="" />
              <p>肾活检染色显示存在IgA沉积、系膜及毛细血管内皮细胞增生、以及节段性肾小球硬化，
                <br class="desktop-only">确诊为IgA肾病</p>
            </div>
          </div>

          <p class="direction bold align-center tablet-desktop-only">点击下方轮播图中的箭头，查看卡洛斯的基线特征</p>
        </div>

      </div>
    </section>

    <div class="temp-section mobile-only">
      <p class="direction bold align-center">Swipe in the carousel below to explore Carlos&rsquo; baseline characteristics</p>
    </div>

    <!-- //////////////////// SECTION 2 ///////////////////// -->

    <section class="" data-section-id="2" data-section-name="Carlos Demographic and Information Carousel" data-dot-label="基线特征">
      <div class="owl-carousel">
        <div class="carousel-block" id="carlos-block-1">
          <h3 class="label">活检时年龄</h3>
          <h4 class="characteristic">40 岁</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>大多数 IgA肾病患者在40岁前确诊<sup>1</sup></span></li>
            <li><span class="bullet">&bull;</span><span>临床表现和疾病进展可能因患者诊断时的年龄而异<sup>2</sup></span></li>
          </ul>

          <div class="footnotes">
            <p><span class="bold">参考文献: 1.</span> Pitcher D, et al. <em>Clin J Am Soc Nephrol</em>.
              2023;18(6):727-738. <br class="large-screens-only"><span class="bold">2.</span> Gutierrez E, et al. <em>Nephrol Dial Transplant</em>.
              2018;33:472-477.</p>
          </div>
        </div>

        <div class="carousel-block" id="carlos-block-2">
          <h3 class="label">种族</h3>
          <h4 class="characteristic">西班牙裔</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>IgA肾病的临床表现和进展在不同种族间存在显著差异<sup>1</sup></span></li>
            <li><span class="bullet">&bull;</span><span>西班牙裔IgA肾病患者的 CKD 进展和 ESKD 的发生率较高，进展至 ESKD 的中位年龄为 46 岁<sup>2</sup></span></li>
          </ul>

          <div class="footnotes">
            <p>CKD：慢性肾脏病； ESKD：终末期肾病</p>
            <p><span class="bold">参考文献: 1.</span> Yeo SC, et al. <em>Nephrology (Carlton)</em>.
              2019;24(9):885-895. <span class="bold">2.</span> Sim J, et al. <em>Nephrol Dial Transplant</em>. 2025:gfaf084.</p>
          </div>
        </div>

        <div class="carousel-block" id="carlos-block-3">
          <h3 class="label">活检时eGFR</h3>
          <h4 class="characteristic">47 mL/min/<br class="mobile-only"/>1.73 m<sup>2</sup></h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>卡洛斯活检时的 eGFR 显示他处于 CKD 3a 期：肾脏损伤导致轻度至中度肾功能丧失</span></li>
            <li><span class="bullet">&bull;</span><span>eGFR 下降是 IgA肾病进展的一个经过验证的风险因素。eGFR 的下降与慢性肾脏病进展和死亡风险密切相关<sup>1</sup></span></li>
          </ul>

          <div class="footnotes">
            <p>CKD：慢性肾脏病；eGFR：估算肾小球滤过率。</p>
            <p><span class="bold">参考文献: 1.</span> Coresh J, et al. <em>JAMA</em>. 2014;311(24):2518-2531.</p>
          </div>
        </div>

        <div class="carousel-block" id="carlos-block-4">
          <h3 class="label">活检时血压</h3>
          <h4 class="characteristic">160/84 mm Hg</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>活检时发现卡洛斯的血压偏高</span></li>
            <li><span class="bullet">&bull;</span><span>研究表明，高血压是 IgA肾病在确诊时进展的临床预测因素<sup>1</sup></span></li>
            <li><span class="bullet">&bull;</span><span>降低高血压可降低进展为肾衰竭的风险<sup>2</sup></span></li>
          </ul>

          <div class="footnotes">
            <p><span class="bold">参考文献: 1.</span> Maixnerova D, et al. <em>J Nephrol</em>. 2016;29(4):535-541.
              <span class="bold">2.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>

        <div class="carousel-block" id="carlos-block-5">
          <h3 class="label">活检时蛋白尿</h3>
          <h4 class="characteristic">6 g/d</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>活检时卡洛斯的蛋白尿水平升高</span>
            </li>
            <li><span class="bullet">&bull;</span><span>蛋白尿是公认的预后标志物，与长期肾脏结局相关，包括eGFR下降和ESKD进展<sup>1,2</sup></span></li>
            <li><span class="bullet">&bull;</span><span>蛋白尿减少与血清肌酐倍增、ESKD及死亡风险呈负相关<sup>2,3</sup></span></li>
          </ul>

          <div class="footnotes">
            <p>eGFR：估算肾小球滤过率；ESKD：终末期肾病</p>
            <p><span class="bold">参考文献: 1.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276. <span
                class="bold">2.</span> Thompson A, et al. <em>Clin J Am Soc Nephrol</em>. 2019;14(3):469-481. <span
                class="bold">3.</span> Inker L, et al. <em>Am J Kidney Dis</em>. 2016;68(3):392-401.</p>
          </div>
        </div>

        <div class="carousel-block" id="carlos-block-6">
          <h3 class="label">活检时ACE<span class="lower">i</span>/ARB使用情况</h3>
          <h4 class="characteristic">未使用</h4>

          <p>ACEi/ARB是指南推荐的支持治疗，但卡洛斯在活检时尚未启动该治疗。<sup>1</sup></p>

          <div class="footnotes">
            <p>ACEi：血管紧张素转换酶抑制剂；ARB：血管紧张素 II  受体拮抗剂</p>
            <p><span class="bold">参考文献: 1.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>

        <div class="carousel-block" id="carlos-block-7">
          <h3 class="label">MEST-C 评分</h3>
          <h4 class="characteristic">M1 E1 S1 T0 C0</h4>

          <p>卡洛斯的活检采用了牛津分型，即MEST-C评分。其活检结果显示 >50% 的肾小球存在系膜细胞增多、毛细血管内细胞增多和节段性肾小球硬化，无肾小管萎缩/间质纤维化或新月体。</p>
          <p>MEST-C评分是重要的早期预后工具，评估 ESKD 进展风险时应予以考虑。<sup>1-3</sup></p>

          <div class="button cta modal-trigger" data-trigger-id="mest-c-score">
            <p>了解更多关于 MEST-C 的信息</p>
          </div>

          <div class="footnotes">
            <p>ESKD：终末期肾病；MEST-C：系膜细胞增生（M）、毛细血管内皮细胞增生（E）、节段性硬化（S）、肾小管萎缩和间质纤维化（T）、新月体（C）；</p>
            <p><span class="bold">参考文献: 1.</span> Cattran DC, et al. <em>Kidney Int Rep</em>.
              2023;8(12):2515-2528. <span class="bold">2.</span> Haaskjold YL, et al. <em>BMC Nephrology</em>.
              2022;23:26. <span class="bold">3.</span> Coppo R, et al. <em>Kidney Int</em>. 2014;86(4):828-836.</p>
          </div>
        </div>

        <div class="carousel-block" id="carlos-block-8">
          <h3 class="label">活检时或活检前免疫抑制剂使用情况</h3>
          <h4 class="characteristic">未使用</h4>

          <p>免疫抑制治疗对IgA肾病患者的临床获益尚未明确，经评估风险与获益可接受时，特定患者人群可考虑采用。<sup>1</sup></p>

          <div class="footnotes">
            <p><span class="bold">参考文献: 1.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>
      </div>

    </section>

    <div class="temp-section">
      <div class="footnotes">
        <p>*本图像经Renal Fellow Network授权使用，来源： Gallan A. Kidney biopsy of the Month. 2019年7月29日在线发表， 可在此处查看 : <a class="format-url link-color" target="_blank"
            href="https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/">https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/</a>.
        </p>
    
        <p>ACE：血管紧张素转换酶；ARB：血管紧张素 Ⅱ 受体阻滞剂；CKD：慢性肾脏病；eGFR：估算肾小球滤过率；IgA：免疫球蛋白A；<br>
          MEST-C：系膜细胞增生（M）、毛细血管内皮细胞增生（E）、节段性硬化（S）、肾小管萎缩和间质纤维化（T）、新月体（C）；PAS：过碘酸-希夫（染色法 ）。</p>
      </div>

      <img class="tablet-only update-path mobile-bio-trigger" id="mobile-bio-trigger" data-tray-id="mobile-bio-tray" src="./assets/images/profiles/mobile-bio-btn.png" alt="Baseline Assessment trigger button"/>
    </div>

    <section class="gray-bg" data-section-id="3" data-section-name="Carlos' Risk of Progression" data-dot-label="进展风险">
      <div class="two-column static">

        <div id="left-bio" class="">
          <img src="./assets/images/profiles/carlos-profile.png" class="update-path bio-pic" alt="" />

          {{> ../templates/carlos-bio }}
        </div>

        <div class="right-side dual-view">
          <h1 class="pat-header">卡洛斯的疾病进展风险</h1>
          <p class="desc-text">根据卡洛斯活检时的临床特征，他可能在50岁前就面临肾衰竭的风险。</p>

          <div class="graph-container">
            <div class="hotspot" id="state-1" data-value="Age 41;2%"></div>
            <div class="hotspot" id="state-2" data-value="Age 42;7%"></div>
            <div class="hotspot" id="state-3" data-value="Age 43;12%"></div>
            <div class="hotspot" id="state-4" data-value="Age 44;18%"></div>
            <div class="hotspot" id="state-5" data-value="Age 45;25%"></div>

            <div class="tablet-desktop-only">
              <img src="./assets/images/profiles/carlos/progression-graph-state-0.png" id="state-0"
                class="graph update-path" alt="Graph showing Carlos' risk of progression" />
              <img src="./assets/images/profiles/carlos/progression-graph-state-1.png" id="state-1"
                class="graph visible update-path" alt="Graph showing Carlos' risk of progression at age 41. 2 percent 1 year after biopsy" />
              <img src="./assets/images/profiles/carlos/progression-graph-state-2.png" id="state-2"
                class="graph update-path" alt="Graph showing Carlos' risk of progression at age 42. 7 percent 2 years after biopsy" />
              <img src="./assets/images/profiles/carlos/progression-graph-state-3.png" id="state-3"
                class="graph update-path" alt="Graph showing Carlos' risk of progression at age 43. 12 percent 3 years after biopsy" />
              <img src="./assets/images/profiles/carlos/progression-graph-state-4.png" id="state-4"
                class="graph update-path" alt="Graph showing Carlos' risk of progression at age 44. 18 percent 4 years after biopsy" />
              <img src="./assets/images/profiles/carlos/progression-graph-state-5.png" id="state-5"
                class="graph update-path" alt="Graph showing Carlos' risk of progression at age 45. 25 percent 5 years after biopsy" />
            </div>
            <div class="mobile-only">
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-state-0-mobile.png" id="state-0"
                class="graph mobile-graph update-path" alt="Graph showing Carlos' risk of progression" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-state-1-mobile.png" id="state-1"
                class="graph mobile-graph visible update-path" alt="Graph showing Carlos' risk of progression at age 41. 2 percent 1 year after biopsy" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-state-2-mobile.png" id="state-2"
                class="graph mobile-graph update-path" alt="Graph showing Carlos' risk of progression at age 42. 7 percent 2 years after biopsy" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-state-3-mobile.png" id="state-3"
                class="graph mobile-graph update-path" alt="Graph showing Carlos' risk of progression at age 43. 12 percent 3 years after biopsy" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-state-4-mobile.png" id="state-4"
                class="graph mobile-graph update-path" alt="Graph showing Carlos' risk of progression at age 44. 18 percent 4 years after biopsy" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-state-5-mobile.png" id="state-5"
                class="graph mobile-graph update-path" alt="Graph showing Carlos' risk of progression at age 45. 25 percent 5 years after biopsy" />
            </div>
          </div>

          <a href="https://qxmd.com/calculate/calculator_499/international-igan-prediction-tool-at-biopsy-adults"
          target="_blank">
            <div class="button cta" id="sect-3-tool-exit">
              <p>查看国际 IgA肾病预测工具</p>
              <img src="./assets/images/external-icon-white.svg" class="update-path" alt="External link icon" />
            </div>
          </a>
        </div>
      </div>

      <div class="footnotes">
        <p><sup>a</sup>疾病进展预测风险是通过国际 IgA肾病预测工具计算，定义为eGFR 下降 50% 或进展至 ESKD 的风险。<sup>1</sup></p>
        <p>*本图像经 Renal Fellow Network 授权使用，来源：Gallan A. Kidney biopsy of the Month. 2019年7月29日在线发表， 可在此处查看 : <a class="format-url link-color" target="_blank"
            href="https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/">https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/</a>.
        </p>
        <p>ACE：血管紧张素转换酶；ARB：血管紧张素 Ⅱ 受体阻滞剂；CKD：慢性肾脏病；eGFR：估算肾小球滤过率；<br>
          MEST-C：系膜细胞增生（M）、毛细血管内皮细胞增生（E）、节段性硬化（S）、肾小管萎缩和间质纤维化（T）、新月体（C）；PAS：过碘酸-希夫（染色法 ）。</p>
        <p><span class="bold">参考文献: 1.</span> Barbour SJ, et al. <em>Kidney Int</em>. 2022;102(1):160-172.</p>
      </div>

      <img class="tablet-only update-path mobile-bio-trigger" id="mobile-bio-trigger-2" data-tray-id="carlos-bio-tray-2" src="./assets/images/profiles/mobile-bio-btn-2.png" alt="Baseline Assessment After 2 Years trigger button"/>
    </section>

    <section class="" data-section-id="4" data-section-name="Carlos' Risk of Progression After Supportive Care" data-dot-label="蛋白尿的影响">
      <div class="two-column static">
        <div id="left-bio" class="">
          <img src="./assets/images/profiles/carlos-profile.png" class="update-path bio-pic" alt="" />

          {{> ../templates/carlos-bio-42 }}
        </div>

        <div class="right-side">
          <h1 class="pat-header">卡洛斯接受支持治疗后<br class="desktop-only">
            的疾病进展风险</h1>

          <p class="desc-text">卡洛斯迅速接受了免疫抑制在内的强化支持治疗。<br>
          在确诊两年后，他的血压得到控制，蛋白尿减半至3 g/d。</p>

          <div class="graph-container">
            <div class="hotspot" id="state-1" data-value="Age 43;5%"></div>
            <div class="hotspot" id="state-2" data-value="Age 44;16%"></div>
            <div class="hotspot" id="state-3" data-value="Age 45;26%"></div>
            <div class="hotspot" id="state-4" data-value="Age 46;36%"></div>
            <div class="hotspot" id="state-5" data-value="Age 47;46%"></div>

            <div class="tablet-desktop-only">
              <img src="./assets/images/profiles/carlos/progression-graph-2-years-state-0.png" id="state-0"
                class="graph update-path"
                alt="Graph showing Carlos' risk of progression one year after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/progression-graph-2-years-state-1.png" id="state-1"
                class="graph visible update-path"
                alt="Graph showing Carlos' risk of progression at age 43. 5 percent risk one year after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/progression-graph-2-years-state-2.png" id="state-2"
                class="graph update-path"
                alt="Graph showing Carlos' risk of progression at age 44. 16 percent risk two years after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/progression-graph-2-years-state-3.png" id="state-3"
                class="graph update-path"
                alt="Graph showing Carlos' risk of progression at age 45. 26 percent risk three years after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/progression-graph-2-years-state-4.png" id="state-4"
                class="graph update-path"
                alt="Graph showing Carlos' risk of progression at age 46. 36 percent risk four years after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/progression-graph-2-years-state-5.png" id="state-5"
                class="graph update-path"
                alt="Graph showing Carlos' risk of progression at age 47. 46% risk five years after stabilization on supportive care" />
            </div>
            <div class="mobile-only">
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-2-years-state-0-mobile.png" id="state-0"
                class="mobile-graph graph update-path"
                alt="Graph showing Carlos' risk of progression one year after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-2-years-state-1-mobile.png" id="state-1"
                class="mobile-graph graph visible update-path"
                alt="Graph showing Carlos' risk of progression at age 43. 5 percent risk one year after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-2-years-state-2-mobile.png" id="state-2"
                class="mobile-graph graph update-path"
                alt="Graph showing Carlos' risk of progression at age 44. 16 percent risk two years after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-2-years-state-3-mobile.png" id="state-3"
                class="mobile-graph graph update-path"
                alt="Graph showing Carlos' risk of progression at age 45. 26 percent risk three years after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-2-years-state-4-mobile.png" id="state-4"
                class="mobile-graph graph update-path"
                alt="Graph showing Carlos' risk of progression at age 46. 36 percent risk four years after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-2-years-state-5-mobile.png" id="state-5"
                class="mobile-graph graph update-path"
                alt="Graph showing Carlos' risk of progression at age 47. 46% risk five years after stabilization on supportive care" />
            </div>
          </div>

          <h4>尽管确诊后就立即开始接受支持<br class="desktop-only">
            治疗，卡洛斯的进展风险仍持续上升。</h4>

          <p class="bold">当前KDIGO指南不建议在非糖尿病的 IgAN 患者中使用SGLT2i ，因其疗效和安全性数据还有待完善。虚拟患者病例采用的治疗依据当前治疗指南制定。<sup>2</sup></p>
        </div>

      </div>

      <div class="footnotes">
        <p>*本图像经 Renal Fellow Network 授权使用，来源：Gallan A. Kidney Biopsy of the Month. 2019 Jul 29.可在此处查看 <a class="format-url link-color" target="_blank"
            href="https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/">https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/</a>.
        </p>
        <p><sup>a</sup>MEST-C评分取自基线活检结果。</p>
        <p><sup>b</sup>疾病进展风险通过国际IgA肾病预测工具计算，定义为 eGFR 下降 50% 或发生 ESKD 的风险。<sup>1</sup></p>
        <p>ACEi：血管紧张素转换酶抑制剂；ARB：血管紧张素II受体阻滞剂；eGFR：估算肾小球滤过率；ESKD：终末期肾病；KDIGO：改善全球肾脏病预后组织；MEST-C：系膜细胞增生（M）、毛细血管内皮细胞增生（E）、节段性硬化（S）、肾小管萎缩和间质纤维化（T）、新月体（C）；PAS：过碘酸-希夫（染色法 ）；SGLT2i：钠 - 葡萄糖协同转运蛋白 2 抑制剂。</p>
        <p><span class="bold">参考文献: 1.</span> Barbour SJ, et al. <em>Kidney Int</em>. 2022;102(1):160-172. <span
            class="bold">2.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
      </div>
    </section>

    <section class="gray-bg" data-section-id="5" data-section-name="Carlos Histopathological Changes Caused by IgAN" data-dot-label="支持治疗后的效果">
      <div class="flex-header">
        <img src="./assets/images/profiles/carlos-profile.png" class="update-path bio-pic desktop-only" alt="" />

        <div>
          <h1 class="pat-header">IgA肾病导致的组织病理学改变</h1>
          <p class="desc-text">卡洛斯成功降低了蛋白尿和血压；然而，Gd-IgA1免疫复合物仍持续在肾脏中沉积，导致组织病理学变化和肾脏损伤。<sup>1</sup></p>
        </div>
      </div>

      <div class="content-lower">
        <p class="subhead">IgA肾病患者接受支持治疗后，即使血压和/或蛋白尿等其他临床指标得以改善，<br class="desktop-only">仍可能随时间持续丧失功能性肾组织。<sup>2</sup>
        </p>

        <div class="divider"></div>

        <h3 class="graph-header">肾脏病理特征的变化</h3>
        <p class="direction">滑动查看组织病理学特征如何随时间变化，并影响肾脏存活率。</p>

        <div class="images-container">
          <div class="left-side">
            <div class="text-bubble visible" id="section-5-state-1">
              <p>活检时，卡洛斯的肾小球存在系膜和毛细血管内细胞增多。部分肾小球已出现硬化，如下图黑色箭头所示。<sup>a</sup></p>

              <div class="gap-10"></div>

              <img src="./assets/images/profiles/carlos/biopsy-stain.png" class="stain update-path"
                alt="PAS staining showing sclerosis in the upper left portion of the glomerulus as indicated by a black arrow." />

              <div class="gap-10"></div>

              <p>图片经许可使用*</p>
            </div>

            <div class="text-bubble" id="section-5-state-2">
              <p>系膜细胞和毛细血管内皮细胞持续增殖，肾小球瘢痕形成并进一步加重。</p>
            </div>

            <div class="text-bubble" id="section-5-state-3">
              <p>系膜区沉积过量 ECM，新月体弥漫性累及整个肾小球，肾小管开始出现萎缩迹象。</p>
            </div>

            <div class="text-bubble" id="section-5-state-4">
              <p>系膜细胞和炎症细胞持续增殖，瘢痕扩散至肾小球的更多区域。</p>
            </div>
          </div>

          <div class="right-side">
            <div class="graphic-container">
              <img src="./assets/images/profiles/carlos/graphic-1.png" id="section-5-state-1" class="update-path graphic visible" 
                alt="Detailed glomerulus structure with mesangial hypercellularity, endocapillary hypercellularity, and segmental sclerosis" />
              <img src="./assets/images/profiles/carlos/graphic-2.png" id="section-5-state-2" class="update-path graphic"
                alt="Detailed glomerulus structure with excess mesangial cells and immune cells" />
              <img src="./assets/images/profiles/carlos/graphic-3.png" id="section-5-state-3" class="update-path graphic"
                alt="Kidney structure showing glomerulosclerosis and tubular atrophy" />
              <img src="./assets/images/profiles/carlos/graphic-4.png" id="section-5-state-4" class="update-path graphic"
                alt="Glomerulus showing sclerosis, mesangial cell proliferation, and immune cells" />

                <div class="histo-tag group-1" id="tag-1">
                  <p>蛋白质</p>
                  <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                  <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
                <div class="histo-tag group-1" id="tag-2">
                  <p>硬化</p>
                  <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                  <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
                <div class="histo-tag group-1" id="tag-3">
                  <p>红细胞</p>
                  <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                  <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
                <div class="histo-tag group-1" id="tag-4">
                  <p>ECM</p>
                  <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                  <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
                <div class="histo-tag group-1" id="tag-5">
                  <p>Gd-IgA1 免疫复合物</p>
                    <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                    <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
                <div class="histo-tag group-1" id="tag-6">
                  <p>免疫细胞</p>
                  <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                  <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
                <div class="histo-tag group-1" id="tag-7">
                  <p>系膜细胞​</p>
                    <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                    <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
                <div class="histo-tag group-3 hidden" id="tag-8">
                  <p>肾小管萎缩</p>
                    <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                    <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
            </div>

            <div class="slider-container conditional-slider-upper">
              <img src="./assets/images/profiles/over-time-slider-1.svg" id="section-5-state-1"
                class="update-path slider-upper slider visible" alt="Slider shown at biopsy stage">
              <img src="./assets/images/profiles/over-time-slider-2.svg" id="section-5-state-2"
                class="update-path slider-upper slider" alt="Slider shown at 2 years">
              <img src="./assets/images/profiles/over-time-slider-3.svg" id="section-5-state-3"
                class="update-path slider-upper slider" alt="Slider shown at 4 years">
              <img src="./assets/images/profiles/over-time-slider-4.svg" id="section-5-state-4"
                class="update-path slider-upper slider" alt="Slider shown at 6 years">

              <input type="range" class="range-slider" id="s6-upper" name="s6-upper" min="1" max="4" value="1" step="1" />
            </div>
          </div>
        </div>

        <div class="slider-container mobile-only">
          <img src="./assets/images/profiles/over-time-slider-1-mobile.png" id="section-5-state-1"
            class="update-path slider-upper mobile-graph slider visible" alt="Slider shown at biopsy stage">
          <img src="./assets/images/profiles/over-time-slider-2-mobile.png" id="section-5-state-2"
            class="update-path slider-upper mobile-graph slider" alt="Slider shown at 2 years">
          <img src="./assets/images/profiles/over-time-slider-3-mobile.png" id="section-5-state-3"
            class="update-path slider-upper mobile-graph slider" alt="Slider shown at 4 years">
          <img src="./assets/images/profiles/over-time-slider-4-mobile.png" id="section-5-state-4"
            class="update-path slider-upper mobile-graph slider" alt="Slider shown at 6 years">

          <input type="range" class="range-slider" id="s6-mobile" name="s6-mobile" min="1" max="4" value="1" step="1" />
        </div>

        <div class="slider-container conditional-slider-lower">
          <img src="./assets/images/profiles/over-time-slider-1.svg" id="section-5-state-1"
            class="update-path slider-upper graph slider visible" alt="Slider shown at biopsy stage">
          <img src="./assets/images/profiles/over-time-slider-2.svg" id="section-5-state-2"
            class="update-path slider-upper graph slider" alt="Slider shown at 2 years">
          <img src="./assets/images/profiles/over-time-slider-3.svg" id="section-5-state-3"
            class="update-path slider-upper graph slider" alt="Slider shown at 4 years">
          <img src="./assets/images/profiles/over-time-slider-4.svg" id="section-5-state-4"
            class="update-path slider-upper graph slider" alt="Slider shown at 6 years">

          <input type="range" class="range-slider" id="s6-conditional" name="s6-conditional" min="1" max="4" value="1" step="1" />
        </div>

        <div class="graphs-container">
          <div class="left-side">
            <div class="tablet-desktop-only">
              <img src="./assets/images/profiles/carlos/pro-over-time-state-1.png" id="section-5-state-1"
                class="update-path graph visible" alt="Graph modeling proteinuria progression over time, starting at biopsy"/>
              <img src="./assets/images/profiles/carlos/pro-over-time-state-2.png" id="section-5-state-2"
                class="update-path graph" alt="Graph showing proteinuria progression level after two years"/>
              <img src="./assets/images/profiles/carlos/pro-over-time-state-3.png" id="section-5-state-3"
                class="update-path graph" alt="Graph showing proteinuria progression level at four years"/>
              <img src="./assets/images/profiles/carlos/pro-over-time-state-4.png" id="section-5-state-4"
                class="update-path graph" alt="Graph showing proteinuria progression level at six years"/>
            </div>
            <div class="mobile-only">
              <img src="./assets/images/profiles/carlos/mobile/pro-over-time-state-1-mobile.png" id="section-5-state-1"
                class="update-path mobile-graph graph visible" alt="Graph modeling proteinuria progression over time, starting at biopsy"/>
              <img src="./assets/images/profiles/carlos/mobile/pro-over-time-state-2-mobile.png" id="section-5-state-2"
                class="update-path mobile-graph graph" alt="Graph showing proteinuria progression level after two years"/>
              <img src="./assets/images/profiles/carlos/mobile/pro-over-time-state-3-mobile.png" id="section-5-state-3"
                class="update-path mobile-graph graph" alt="Graph showing proteinuria progression level at four years"/>
              <img src="./assets/images/profiles/carlos/mobile/pro-over-time-state-4-mobile.png" id="section-5-state-4"
                class="update-path mobile-graph graph" alt="Graph showing proteinuria progression level at six years"/>
            </div>
          </div>
          <div class="right-side">
            <div class="tablet-desktop-only">
              <img src="./assets/images/profiles/carlos/egfr-over-time-state-1.png" id="section-5-state-1"
                class="update-path graph visible" alt="Graph modeling eGFR decline over time, starting at biopsy"/>
              <img src="./assets/images/profiles/carlos/egfr-over-time-state-2.png" id="section-5-state-2"
                class="update-path graph" alt="Graph showing eGFR after two years"/>
              <img src="./assets/images/profiles/carlos/egfr-over-time-state-3.png" id="section-5-state-3"
                class="update-path graph" alt="Graph showing eGFR after four years"/>
              <img src="./assets/images/profiles/carlos/egfr-over-time-state-4.png" id="section-5-state-4"
                class="update-path graph" alt="Graph showing eGFR after six years"/>
            </div>
            <div class="mobile-only">
              <img src="./assets/images/profiles/carlos/mobile/egfr-over-time-state-1-mobile.png" id="section-5-state-1"
                class="update-path mobile-graph graph visible" alt="Graph modeling eGFR decline over time, starting at biopsy"/>
              <img src="./assets/images/profiles/carlos/mobile/egfr-over-time-state-2-mobile.png" id="section-5-state-2"
                class="update-path mobile-graph graph" alt="Graph showing eGFR after two years"/>
              <img src="./assets/images/profiles/carlos/mobile/egfr-over-time-state-3-mobile.png" id="section-5-state-3"
                class="update-path mobile-graph graph" alt="Graph showing eGFR after four years"/>
              <img src="./assets/images/profiles/carlos/mobile/egfr-over-time-state-4-mobile.png" id="section-5-state-4"
                class="update-path mobile-graph graph" alt="Graph showing eGFR after six years"/>
            </div>
          </div>
        </div>

        <div class="slider-container">
          <div class="tablet-desktop-only">
            <img src="./assets/images/profiles/over-time-slider-1.svg" id="section-5-state-1"
              class="update-path slider-lower slider visible" alt="Slider shown at biopsy stage"/>
            <img src="./assets/images/profiles/over-time-slider-2.svg" id="section-5-state-2"
              class="update-path slider-lower slider" alt="Slider shown at 2 years"/>
            <img src="./assets/images/profiles/over-time-slider-3.svg" id="section-5-state-3"
              class="update-path slider-lower slider" alt="Slider shown at 4 years"/>
            <img src="./assets/images/profiles/over-time-slider-4.svg" id="section-5-state-4"
              class="update-path slider-lower slider" alt="Slider shown at 6 years"/>
          </div>
          <div class="mobile-only">
            <img src="./assets/images/profiles/over-time-slider-1-mobile.png" id="section-5-state-1"
              class="update-path slider-lower mobile-graph slider visible" alt="Slider shown at biopsy stage"/>
            <img src="./assets/images/profiles/over-time-slider-2-mobile.png" id="section-5-state-2"
              class="update-path slider-lower mobile-graph slider" alt="Slider shown at 2 years"/>
            <img src="./assets/images/profiles/over-time-slider-3-mobile.png" id="section-5-state-3"
              class="update-path slider-lower mobile-graph slider" alt="Slider shown at 4 years"/>
            <img src="./assets/images/profiles/over-time-slider-4-mobile.png" id="section-5-state-4"
              class="update-path slider-lower mobile-graph slider" alt="Slider shown at 6 years"/>
          </div>

          <input type="range" class="range-slider" id="s6-lower" name="s6-lower" min="1" max="4" value="1" step="1" />
        </div>
      </div>

      <div class="footnotes">
        <p>上图仅供参考，旨在说明 IgA&#32958;&#30149;&#26399;&#38388;&#21487;&#33021;&#20986;&#29616;&#30340;&#28508;&#22312;&#32452;&#32455;&#30149;&#29702;&#23398;&#21464;&#21270;，而并非旨在提供这些变化进展的具体信息，也不用于指导治疗决策。<br class="desktop-only">
          蛋白尿的变化和 eGFR 的变化均根据临床试验和队列研究结果趋势设定。<sup>3-6</sup></p>
        <p>*图片经 Renal Fellow Network授权使用，来源：Gallan A. Kidney biopsy of the Month.2019年7月29日在线发表，可在此处查看: <a class="format-url link-color" target="_blank"
            href="https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/">https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/</a>.
        </p>
        <p><sup>a</sup>PAS染色显示肾小球左上象限存在硬化（如黑色箭头所示）。单个肾小球可能无法全面反映MEST-C评分所有组分。</p>
        <p>ECM：细胞外基质；eGFR：估算肾小球滤过率；Gd-IgA1：半乳糖缺陷型 IgA1；MEST-C：系膜细胞增生（M）、毛细血管内皮细胞增生（E）、节段性硬化（S）、肾小管萎缩和间质纤维化（T）、新月体（C）；PAS：过碘酸-希夫（染色法 ）。</p>
        <p><span class="bold">参考文献: 1.</span> Lai KN, et al. <em>Nat Rev Dis Primers</em>. 2016;2:16001. <span
            class="bold">2.</span> Barratt J, et al. <em>Kidney Int</em>. 2023;103(2):391-402. <span
            class="bold">3.</span> Pitcher D, et al. <em>Clin J Am Soc Nephrol</em>. 2023;18(6):727-738. <span
            class="bold">4.</span> Faucon AL, et al. <em>Nephrol Dial Transplant</em>. 2024;30:gfae085. <span
            class="bold">5.</span> Rovin BH, et al. <em>Lancet</em>. 2023;402(10417):2077-2090. <span
            class="bold">6.</span> Lafayette R, et al. <em>Lancet</em>. 2023;402:859-870.</p>
      </div>
    </section>

    <section class="gray-bg" data-section-id="6" data-section-name="Carlos Impact of MEST-C Lesions" data-dot-label="组织病理学变化">
      <div class="flex-header">
        <img src="./assets/images/profiles/carlos-profile.png" class="update-path bio-pic desktop-only" alt="" />

        <div>
          <h1 class="pat-header">MEST-C 病变的临床意义</h1>
          <p class="desc-text">MEST-C 病变可协助肾病科医生为每位患者确定合适的管理策略</p>
        </div>
      </div>

      <p class="bold">点击下方了解更多关于 MEST-C 病变的信息。</p>

      <div id="content-box">

        <div class="hotspot-container">
          <div class="content-hotspot" id="content-state-1"></div>
          <div class="content-hotspot" id="content-state-2"></div>
        </div>

        <div class="large-screens-only">
          <img src="./assets/images/profiles/carlos/sect-6-box-state-1.png" id="content-state-1"
            class="content-img visible update-path" alt="Illustration of inflammatory lesions (mesangial and endocapillary hypercellularity), impairing glomerular filtration." />
          <img src="./assets/images/profiles/carlos/sect-6-box-state-2.png" id="content-state-2"
            class="content-img update-path" alt="Illustration of chronic lesions (segmental glomerulosclerosis and tubular atrophy), indicating chronic irreversible loss of kidney function" />
        </div>
        <div class="mobile-only">
          <img src="./assets/images/profiles/carlos/mobile/sect-6-box-state-1-mobile.png" id="content-state-1"
            class="content-img mobile-graph visible update-path" alt="Illustration of inflammatory lesions (mesangial and endocapillary hypercellularity), impairing glomerular filtration." />
          <img src="./assets/images/profiles/carlos/mobile/sect-6-box-state-2-mobile.png" id="content-state-2"
            class="content-img mobile-graph update-path" alt="Illustration of chronic lesions (segmental glomerulosclerosis and tubular atrophy), indicating chronic irreversible loss of kidney function" />
        </div>

      </div>

      <div class="footnotes tablet-desktop-only">
          <p>CKD：慢性肾脏病；IgA：免疫球蛋白A；MEST-C：系膜细胞增生（M）、毛细血管内皮细胞增生（E）、节段性硬化（S）、肾小管萎缩和间质纤维化（T）、新月体（C）。</p>
          <p><span class="bold">参考文献：1.</span> Pattrapornpisut P, et al. <em>Am J Kidney Dis</em>. 2021;78(3):429-441. <span class="bold">2.</span> Wendt R, et al. <em>Biomedicines</em>. 2024;12(10):2259. <span class="bold">3.</span> Trimarchi H, et al. <em>Kidney Int</em>. 2017;91(5):1014-1021. <span class="bold">4.</span> Mitrotti A, et al. <em>Pediatr Nephrol</em>. 2024;39(6):1685-1707. <span class="bold">5.</span> Filippone EJ, et al. <em>Front Immunol</em>. 2024;15:1436923. <span class="bold">6.</span> Wendt R, et al. <em>Biomedicines</em>. 2024;12(10):2259. <span class="bold">7.</span> Caster DJ, et al. <em>Kidney Int Rep</em>. 2023;8(9):1792-1800.</p>
      </div>
    </section>

    <section class="gray-bg acc-section" data-section-id="7" data-section-name="Carlos Impact of eGFR Decline on Progression to ESKD" data-dot-label="eGFR 下降对疾病进<br>展的影响">

      <div class="acc-header">
        <p>了解更多卡洛斯的 eGFR 如何随时间下降的信息</p>
        <img src="./assets/images/acc-arrow.svg" class="update-path acc-arrow" alt=""/>
      </div>

      <div class="acc-content">
        <div class="flex-header">
          <img src="./assets/images/profiles/carlos-profile.png" class="update-path bio-pic desktop-only" alt="" />
  
          <div>
            <h1 class="pat-header">eGFR下降对疾病进展至肾衰竭的影响</h1>
            <p class="desc-text">根据卡洛斯的eGFR下降速度，他可能在10年内发展至肾衰竭。</p>
          </div>
        </div>
  
        <p class="bold">如果卡洛斯的eGFR下降趋于稳定，可延缓肾衰竭的发生。</p>
        <p class="direction">点击下方按钮，查看不同eGFR下降速率对肾衰竭进展的影响</p>
  
        <div class="graph-container">
          <div class="tablet-desktop-only">
            <img src="./assets/images/profiles/carlos/section-7-graph-state-0.png" id="0" class="update-path graph"
              alt="Graph depicting changes in eGFR over time" />
            <img src="./assets/images/profiles/carlos/section-7-graph-state-1.png" id="state-3" class="update-path visible graph"
              alt="Graph depicting changes in eGFR over time at a loss of 5 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/carlos/section-7-graph-state-2.png" id="state-2" class="update-path graph"
              alt="Graph depicting changes in eGFR over time at a loss of 3 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/carlos/section-7-graph-state-3.png" id="state-1" class="update-path graph"
              alt="Graph depicting changes in eGFR over time at a loss of 2 mL/min/1.73 m2 per year" />
            </div>
            <div class="mobile-only">
            <img src="./assets/images/profiles/carlos/mobile/section-7-graph-state-0-mobile.png" id="0" class="update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time" />
            <img src="./assets/images/profiles/carlos/mobile/section-7-graph-state-1-mobile.png" id="state-3" class="visible update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time at a loss of 5 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/carlos/mobile/section-7-graph-state-2-mobile.png" id="state-2" class="update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time at a loss of 3 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/carlos/mobile/section-7-graph-state-3-mobile.png" id="state-1" class="update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time at a loss of 2 mL/min/1.73 m2 per year" />
          </div>
  
          <div class="hotspot" id="state-1" data-value="Annual eGFR loss: -2 mL/min/1.73 m^2/year"></div>
          <div class="hotspot" id="state-2" data-value="Annual eGFR loss: -3 mL/min/1.73 m^2/year"></div>
          <div class="hotspot" id="state-3" data-value="Annual eGFR loss: -5 mL/min/1.73 m^2/year"></div>
  
          <div class="upper-hotspots">
            <div class="hotspot lower-hotspot" id="state-3" data-value="Annual eGFR loss: -5 mL/min/1.73 m^2/year"></div>
            <div class="hotspot lower-hotspot" id="state-2" data-value="Annual eGFR loss: -3 mL/min/1.73 m^2/year"></div>
            <div class="hotspot lower-hotspot" id="state-1" data-value="Annual eGFR loss: -2 mL/min/1.73 m^2/year"></div>
          </div>
        </div>
  
        <div class="footnotes">
          <p>CKD：慢性肾脏病；eGFR：估算肾小球滤过率。</p>
        </div>
      </div>

    </section>

    <section class="switch-pat-section" data-section-name="Switch Patient">
      <h2 class="yellow-header">选择另一名虚拟患者</h2>

      <div class="flex">
        <div class="profile nav-el" data-nav-url="progression/sarah" data-exit-url="progression/sarah">
          <img src="./assets/images/profiles/sarah-profile.png" class="update-path" alt="" />
          <h3>莎拉</h3>
        </div>
        <div class="profile nav-el" data-nav-url="progression/mark" data-exit-url="progression/mark">
          <img src="./assets/images/profiles/mark-profile.png" class="update-path" alt="" />
          <h3>马克</h3>
        </div>
      </div>

      <img src="./assets/images/or-line-graphic.png" class="or-line update-path" alt="Or" />

      <div class="button nav-el" id="discover" data-nav-url="pathogenesis/index" data-exit-url="pathogenesis/mark">
        <p>探索 IgA肾病的疾病机制</p>
      </div>
    </section>

    {{> ../templates/footer-el }}

  </main>

  <script type="text/javascript" src="../static.bundle.js" charset="utf-8"></script>
</body>

</html>